Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06743113 · ClinicalTrials.gov registry record · NA
Hypoxic Red Blood Cells in Sickle Cell Anemia
A NA study, sponsored by Hemanext.
- Not yet
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT06743113 is a NA study that has not yet begun recruiting, run by Hemanext. The registered enrollment target is 48 participants.
The verdict
NCT06743113, a NA study, has not yet begun recruiting, sponsored by Hemanext.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.
Interventions
- DEVICE Hemanext ONE System
- DEVICE Conventional RBCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2026-03 |
| Est. Completion | 2028-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06743113
The ClinicalTrials.gov registry entry for NCT06743113 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hemanext, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hemanext ONE System is the first listed.
NCT06743113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06743113 about?
NCT06743113 is a clinical study titled "Hypoxic Red Blood Cells in Sickle Cell Anemia". The overall objective of this study is to evaluate the effectiveness and safety of transfusing hypoxic red blood cells manufactured with the Hemanext ONE system in patients with sickle cell anemia. The Hemanext ONE device was cleared through the De Novo process in September 2023.
What is the current status of trial NCT06743113?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 48 participants. The study started on 2026-03. Estimated completion is 2028-09.
What interventions are being tested in trial NCT06743113?
The interventions under investigation include: Hemanext ONE System (DEVICE), Conventional RBCs (DEVICE).
Who is sponsoring clinical trial NCT06743113?
This trial is sponsored by Hemanext, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.